41,315 Shares in Anika Therapeutics Inc. $ANIK Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new stake in Anika Therapeutics, purchasing 41,315 shares valued at approximately $621,000, indicating institutional interest in the biotechnology company.
• Recently, several hedge funds increased their holdings in Anika Therapeutics, demonstrating growing investor confidence, with institutional ownership now at 91.53%.
• Analysts have recently revised their ratings and price targets for Anika Therapeutics, with a consensus rating of "Strong Buy" and an average target price of $18.00.

Nuveen LLC acquired a new stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 41,315 shares of the biotechnology company's stock, valued at approximately $621,000. Nuveen LLC owned approximately 0.29% of Anika Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Wellington Management Group LLP lifted its position in Anika Therapeutics by 3.7% during the fourth quarter. Wellington Management Group LLP now owns 39,785 shares of the biotechnology company's stock valued at $655,000 after buying an additional 1,407 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Anika Therapeutics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company's stock valued at $122,000 after purchasing an additional 1,759 shares during the last quarter. Barclays PLC lifted its position in Anika Therapeutics by 6.4% in the fourth quarter. Barclays PLC now owns 34,757 shares of the biotechnology company's stock worth $571,000 after purchasing an additional 2,093 shares during the period. Tower Research Capital LLC TRC raised its holdings in Anika Therapeutics by 412.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,890 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 2,326 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Anika Therapeutics during the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 91.53% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ANIK shares. Barrington Research reduced their price target on Anika Therapeutics from $19.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, July 31st. Wall Street Zen downgraded Anika Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Strong Buy" and an average target price of $18.00.

Anika Therapeutics Stock Down 0.1%

Shares of ANIK stock traded down $0.01 on Monday, reaching $8.93. 30,991 shares of the stock were exchanged, compared to its average volume of 88,978. The firm has a 50 day moving average of $9.82 and a two-hundred day moving average of $12.37. The stock has a market cap of $128.77 million, a P/E ratio of -2.15 and a beta of 0.63. Anika Therapeutics Inc. has a 1-year low of $7.87 and a 1-year high of $26.00.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.